Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ETUpcoming Data Readout for Cohort 1 of OPGx-BEST1 ...

Chengdu Origen, Vanotech receive US FDA’s IND application clearance of KHN921 to treat hypertrophic cardiomyopathy associated with MYBPC3 mutations: Chengdu, China Saturday, May ...

About Chengdu Origen and Vanotech Chengdu Origen is a clinical-stage gene therapy company focused on developing gene therapy for unmet medical needs and providing meaningful clinical benefits for ...

From revamping security culture to transformation threat hunting operations, 2026’s award-winning projects underscore the ...

Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S.

Detailed price information for Libra Energy Materials Inc. (LIBR-CN) from The Globe and Mail including charting and trades.

Investigational New Drug application for KHN921 received "study may proceed" from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment o ...

The modern threat to the United States homeland is no longer characterized only by bombs, border infiltration, or spectacular ...

Detailed price information for Great Atlantic Resources Corp (GR-X) from The Globe and Mail including charting and trades.

Paul Keating’s warning that Australia risked becoming a “banana republic” if competitiveness did not improve was made 40 ...

HM Exploration Corp. ("HM Exploration" or "HM" or the "Company") (CSE:HM) (FSE:X5H) is pleased to announce that it has ...

Preclinical AVB-406 data presented in three oral presentations demonstrate the power of the vMiXTM RNAi platform and support planned clinical initiation for Alzheimer’s disease by the end of 2026 Prec ...